secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jasper Therapeutics, Inc. (JSPR)
CIK:        0001788028
Form:       8-K
Filed at:   2026-07-31T10:06:58+00:00
Accession:  0001213900-26-083563
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Jasper Therapeutics confirms CVR terms: $30M milestone if FDA issues Priority Review Voucher for briquilimab by Dec 2028
--------------------------------------------------------------------------------

- Each share of common stock as of July 16, 2026 (closing date) receives one CVR.
- CVRs entitle holders to pro rata share of $30M if FDA issues Priority Review Voucher for briquilimab on or before Dec 31, 2028.
- If milestone achieved and change of control occurs, payment on earlier of change of control consummation or 90 days after monetization event.
- CVRs are non-transferable, not certificated, not registered with SEC, not listed on any exchange.
- CVRs continue if milestone achieved but monetization not yet occurred; payment due 90 days after monetization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1788028/000121390026083563/0001213900-26-083563-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1788028/000121390026083563/ea0299917-8k_jasper.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-083563

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer